PsiThera

Executive Summary

PsiThera is a private biotechnology company founded in 2018 and headquartered in San Diego, CA, focused on developing oral small-molecule therapeutics for validated immunology and inflammatory disease targets, particularly within the TNF superfamily. The company leverages a proprietary computational platform that models protein dynamics to enable drug design against targets traditionally considered difficult to drug, such as those currently addressed only by injectable biologics. By targeting the TNF superfamily with oral formulations, PsiThera aims to improve patient convenience, reduce healthcare costs, and expand therapeutic options for chronic inflammatory conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. While still in the preclinical stage, PsiThera's differentiated approach combining computational drug discovery with a validated target class positions it to attract further investment and advance toward clinical development. The company has not publicly disclosed pipeline specifics or funding history, suggesting it remains in early private financing stages. If successful, PsiThera could disrupt the TNF inhibitor market, currently dominated by injectable biologics, by offering oral alternatives with potentially improved pharmacokinetics and patient adherence. Key upcoming milestones include securing additional capital, selecting a lead candidate for IND enabling studies, and releasing preclinical proof-of-concept data.

Upcoming Catalysts (preview)

• Q3 2026Series A or B financing to fund IND-enabling studies70% success
• Q4 2026Nomination of lead oral small-molecule candidate for TNF target60% success
• Q1 2027Preclinical efficacy data readout in validated animal model50% success